1,327 Spam-Free Article(s) Found
Symbol Name Last Close Mkt Cap DailyStocks'
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Monday’s Close
NVS Novartis AG $85.13 $197.65B Uptrend
Article Searches
Looking Through A Global Lens Part I: Probabilities And Opportunity In Japan https://seekingalpha.com/article/4242782-looking-global-lens-part-probabilities-opportunity-japan?source=feed_tag_etf_portfolio_strategy Feb 21, 2019 - It is a statistical fact that investors overweight their home country. For U.S. citizens, this is least detrimental since it's the highest weighted (~39%) globally. It is still inefficient, however.Wh
Roche's (RHHBY) BLA for Lymphoma Drug Gets Priority Review http://www.zacks.com/stock/news/355489/roches-rhhby-bla-for-lymphoma-drug-gets-priority-review?cid=CS-ZC-FT-355489 Feb 19, 2019 - The FDA accepts Roche's (RHHBY) BLA for polatuzumab vedotin and NDAs for entrectinib, and grants Priority Review status to the applications.
Teva Is Cheap And It Can Get Cheaper https://seekingalpha.com/article/4242115-teva-cheap-can-get-cheaper?source=feed_tag_israel Feb 19, 2019 - Since the acquisition of Actavis, Teva's balance sheet and cash flow were destroyed. It now has focused relentlessly on realigning its strategy and restoring the balance sheet.Halfway through now, it
Incyte (INCY) Q4 Earnings Miss Estimates, Revenues Beat http://www.zacks.com/stock/news/354853/incyte-incy-q4-earnings-miss-estimates-revenues-beat?cid=CS-ZC-FT-354853 Feb 14, 2019 - Incyte's (INCY) fourth-quarter earnings miss estimates but revenues beat the same on strong Jakafi sales.
Key Takeaways from Eli Lilly's (LLY) Q4 Earnings Report http://www.zacks.com/stock/news/354373/key-takeaways-from-eli-lillys-lly-q4-earnings-report?cid=CS-ZC-FT-354373 Feb 13, 2019 - Here are the key takeaways from Eli Lilly's (LLY) fourth-quarter earnings conference call.
Top Research Reports for ExxonMobil, Merck & Danaher http://www.zacks.com/research-daily/213347/top-research-reports-for-exxonmobil-merck-danaher?cid=CS-ZC-FT-213347 Feb 13, 2019 - Top Research Reports for ExxonMobil, Merck & Danaher
AbbVie Suffers Market Loss For Humira In Europe, But The U.S. Is A Different Story https://seekingalpha.com/article/4240000-abbvie-suffers-market-loss-humira-europe-u-s-different-story?source=feed_sector_healthcare Feb 11, 2019 - AbbVie missed its Q4 earnings expectations, but it does have many other products to help it get back on track in the coming quarters.The big loss for the quarter was due to international sales of Humi
Is a Disappointment in Store for Incyte (INCY) Q4 Earnings? http://www.zacks.com/stock/news/353654/is-a-disappointment-in-store-for-incyte-incy-q4-earnings?cid=CS-ZC-FT-353654 Feb 11, 2019 - Investors are looking forward to Jakafi's performance and other pipeline updates when Incyte (INCY) reports Q4 results on Feb 14.
Incyte Down as FDA Extends Review Period of Jakafi for GVHD http://www.zacks.com/stock/news/353405/incyte-down-as-fda-extends-review-period-of-jakafi-for-gvhd?cid=CS-ZC-FT-353405 Feb 08, 2019 - The FDA extends the review period of Incyte's (INCY) sNDA for the label expansion of Jakafi for the treatment of acute GVHD.
Lilly Q4: Looking At Low Verzenio Sales And The Loxo Oncology Acquisition https://seekingalpha.com/article/4239475-lilly-q4-looking-low-verzenio-sales-loxo-oncology-acquisition?source=feed_sector_healthcare Feb 08, 2019 - Lilly's earnings fall in line with expectations, modest revenue beat from higher than anticipated performance in Mature Brands.Verzenio sales were much lower than expectations, reflecting competitive

Pages: 123456...133

Page 1>

Related Companies

Name Exchange Price Mkt Cap
MRK Merck & Company, Inc. NYSE $70.42 $187.28B
ABBV AbbVie Inc. NYSE $95.37 $144.42B
PFE Pfizer, Inc. NYSE $43.01 $252.13B
ABT Abbott Laboratories NYSE $67.67 $118.71B
NVO Novo Nordisk A/S NYSE $47.64 $114.84B
Sector: Health Care > Industry: Major Pharmaceuticals
DeepLinks for Novartis AG
NVS - Google Finance https://www.google.com/finance?q=NVS Industry related info and international coverage Summary News
NVS - Bloomberg http://www.bloomberg.com/research/stocks/snapshot/snapshot.asp?ticker=NVS Original news and commentary from Bloomberg Charts Financials with pensions Snapshot Earnings Transactions People Options